Immuron builds cash and clinical optionality after record FY26 sales

Travelan drives record commercial sales

Immuron Limited (ASX:IMC; NASDAQ:IMRN) has paired its strongest annual sales performance with a substantial improvement in liquidity, although the commercial business remains loss-making. Revenue from hyperimmune products rose 6% to A$7.71 million in FY26, with Travelan accounting for the overwhelming majority of sales.

Australian Travelan sales increased 9% to A$5.67 million, while US sales rose 7% to A$1.77 million. Canada moved in the opposite direction, falling to A$165,669 from A$378,706. ProIBS contributed A$85,221 after its Australian launch in October 2025, giving Immuron a second commercial product but only a modest initial contribution.

The figures build on the company’s previously reported commercial momentum, including the sixteen percent Q3 sales rise, but the annual result shows the US channel now represents a meaningful part of Travelan’s sales mix. Gross profit rose to A$4.98 million, although the gross margin eased to 64.5% from 65.4% as cost of goods sold increased faster than revenue.

Loss narrows as research spending falls

Immuron’s net loss narrowed 29% to A$3.68 million, from A$5.22 million a year earlier. Operating expenses fell by A$1.82 million to A$9.71 million, led by a 46% reduction in research and development expenditure to A$1.93 million. The report attributes the decline partly to reduced development activity after the Uniformed Services University’s Travelan field study failed to reach statistical significance on its primary endpoint in December 2025.

That improvement should not be mistaken for profitability. Immuron used A$3.26 million in operating cash during the year and finished with accumulated losses of A$84.97 million. Its cash balance nevertheless climbed to A$9.02 million from A$2.83 million, primarily reflecting equity issued through its US at-the-market facility as well as the maturity of a term deposit. Management says existing resources are expected to support operations for at least 12 months from the report date, but the company also states that further funding may be required as development programs progress.

IMM-529 moves towards partnered development

The strategic centre of gravity is now IMM-529, Immuron’s oral investigational therapy for Clostridioides difficile infection. The FDA approved its Investigational New Drug application in November 2025, allowing the planned Phase 2 study to proceed. The proposed trial would enrol up to 60 patients in Australia and test IMM-529 alongside standard of care against placebo plus standard of care, with safety, symptoms, mortality and recurrence among the measures under consideration.

Immuron is not planning to carry the full development burden alone. It engaged Pullan Consulting in July 2026 to seek a partner capable of funding clinical development through regulatory approval and commercialisation. The company cites an external opportunity assessment projecting potential annual revenue of US$400 million if IMM-529 proves efficacious and secures a favourable position in the treatment pathway. That figure is a scenario, not current revenue, and the candidate has not received marketing approval.

US ProIBS distribution adds a second growth test

Immuron has also secured an exclusive US distribution agreement with Calmino Group AB for ProIBS. The product is intended to be launched in the United States as a dietary supplement, with Immuron responsible for marketing, regulatory and distribution costs. The agreement runs for an initial three years from the first sale, subject to sales requirements and extension provisions.

The US launch gives Immuron another route to expand beyond Travelan, but the filing does not disclose the commercial pricing, minimum order volumes or marketing-spend requirements in full. Execution will therefore matter more than the existence of the agreement: ProIBS has generated only A$85,221 in its first Australian reporting year, and the US opportunity remains at an early commercial stage.

Inventory weakness puts reporting controls under scrutiny

The most direct governance warning in the report is a material weakness in internal control over financial reporting relating to inventory recording, classification, valuation and reconciliation, including associated cost of goods sold. Immuron implemented a new inventory system during the year and held stock at new warehouse and third-party locations. Grant Thornton identified inventory as a key audit matter, with total inventory recorded at A$2.27 million.

Management has begun remediation through more detailed inventory listings, periodic cycle counts, reconciliation to the general ledger and tighter review of manual worksheets. The weakness will not be considered resolved until the controls operate effectively for a sufficient period. For a company whose commercial sales depend on outsourced manufacturing and distributed inventory, the next test is not simply whether revenue continues to grow, but whether the systems supporting those numbers can withstand scrutiny.